CommercialCoverageMedium impact
Blinatumomab (Blincyto) (CPB 0891, reviewed 2025-10-30)
Aetna·Oncology, Hematology, Pediatrics·Medical Policy
Effective date
Oct 30, 2025
We identified it
Aug 12, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0891 for blinatumomab (Blincyto), a bispecific CD19-directed CD3 T-cell engager used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). The policy clarifies medical necessity criteria for commercial plans, specifying coverage for induction therapy with tyrosine kinase inhibitors, consolidation/maintenance therapy, and relapsed/refractory disease, while designating all other indications as experimental/investigational. This is a fresh policy update (1 day old) requiring immediate implementation.
Action Required
By 2025-11-15: Billing team must update claims submission procedures and prior authorization requirements in billing system for blinatumomab (J9039) for Aetna commercial plans. (1) Add requirement that all blinatumomab claims must include ICD-10 diagnosis codes C91.00, C91.01, or C91.02 to qualify for coverage. (2) Implement hard-stop rule: claims with ALL diagnoses outside these codes will automatically deny as experimental/investigational. (3) Verify that chemotherapy administration codes (96413-96417) and infusion code (38242) are linked to J9039 claims. (4) Update prior authorization templates to require documentation that blinatumomab is being used for: induction therapy (Philadelphia chromosome-positive with tyrosine kinase inhibitor), consolidation/maintenance therapy, OR relapsed/refractory disease. (5) Flag for rejection any prior auth requests citing acute myeloid leukemia, non-Hodgkin's lymphoma, solid tumors, or other non-covered indications. (6) Educate providers and oncology staff that combined blinatumomab + tyrosine kinase inhibitor for relapsed Philadelphia chromosome-positive leukemia is NOT covered (experimental). Failure to implement these changes will result in claim denials and rework.